Literature DB >> 17824840

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.

Roland D Chapurlat1, Monique Arlot, Brigitte Burt-Pichat, Pascale Chavassieux, Jean Paul Roux, Nathalie Portero-Muzy, Pierre D Delmas.   

Abstract

UNLABELLED: We sought whether microdamage could rise in postmenopausal osteoporotic women on long-term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover.
INTRODUCTION: Animal studies suggest that bisphosphonates (BPs) could increase microdamage frequency in a dose-dependent manner, caused by excessively suppressed bone turnover. However, there is limited data in humans receiving BP therapeutic doses for >3 yr.
MATERIALS AND METHODS: We measured microcrack frequency and histomorphometry parameters on transiliac bone biopsies in 50 postmenopausal osteoporotic women (mean age = 68 yr) who had received BP therapy (3 on intravenous pamidronate, 37 on oral alendronate, and 10 on oral risedronate) for at least 3 yr (mean treatment duration = 6.5 yr). We compared these results with transiliac bone biopsies obtained from 12 cadavers. We used bulk staining with green calcein as a fluorochrome. The microcracks were quantified in three 100-microm-thick sections using optic microscopy and were confirmed by laser confocal microscopy. Microcrack frequency (number of microcracks/mm2 of bone tissue) was compared between treated women and controls using nonparametric tests. We also explored predictors of microcrack frequency, including age, duration of BP therapy, and activation frequency.
RESULTS: Among treated women, cancellous bone microcrack frequency was low (mean, 0.13 microcracks/mm2) and did not differ significantly from that observed in controls (0.05 microcracks/mm2; p = 0.59). Of note, 54% of the treated women and 58% of the controls had no observable microcracks. There was no association between microcrack frequency and the duration of BP therapy (for microcracks/mm2 and duration, Spearman r = 0.04, p = 0.80) and between patients' ages and the number of microcracks (Spearman r = -0.09, p = 0.61). Although bone remodeling parameters were suppressed in treated women, we found no relationship between microcrack density and activation frequency (Spearman r = -0.003, p = 0.99). Also, microcrack frequency was not increased in women with prevalent vertebral fracture compared with those without fractures.
CONCLUSIONS: Among postmenopausal osteoporotic women on long-term BPs, microcrack frequency in the iliac bone is low, despite a marked reduction of bone turnover.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17824840     DOI: 10.1359/jbmr.070609

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  40 in total

1.  Bone microdamage.

Authors:  R D Chapurlat
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

2.  Methodological approach for the detection of both microdamage and fluorochrome labels in ewe bone and human trabecular bone.

Authors:  Brigitte Burt-Pichat; Hélène Follet; Gwendoline Toulemonde; Monique Arlot; Pierre Delmas; Roland Chapurlat
Journal:  J Bone Miner Metab       Date:  2011-07-13       Impact factor: 2.626

3.  Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.

Authors:  Catherine Delguste; Michèle Doucet; Annick Gabriel; Jérôme Guyonnet; Olivier M Lepage; Hélène Amory
Journal:  Can J Vet Res       Date:  2011-04       Impact factor: 1.310

4.  One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.

Authors:  Jessica M O'Neal; Tamim Diab; Matthew R Allen; Brani Vidakovic; David B Burr; Robert E Guldberg
Journal:  Bone       Date:  2010-05-16       Impact factor: 4.398

Review 5.  Review: epidemiology and pathophysiology of atypical femur fractures.

Authors:  Alvin C Ng; Meng Ai Png; David T Chua; Joyce S B Koh; Tet Sen Howe
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 6.  Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.

Authors:  Piet Geusens
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

Review 7.  Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.

Authors:  Jordi Bover; Lucía Bailone; Víctor López-Báez; Silvia Benito; Paola Ciceri; Andrea Galassi; Mario Cozzolino
Journal:  J Nephrol       Date:  2017-04-21       Impact factor: 3.902

Review 8.  Bone microdamage: a clinical perspective.

Authors:  R D Chapurlat; P D Delmas
Journal:  Osteoporos Int       Date:  2009-03-17       Impact factor: 4.507

9.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

10.  Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy.

Authors:  Shinichiro Kuroshima; Rodan B Mecano; Ryuichiro Tanoue; Kiyono Koi; Junro Yamashita
Journal:  J Periodontol       Date:  2013-05-20       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.